Orphan Drug Designation

Welcome to

CHORD Therapeutics

Drug development for rare neurological diseases


Geneva, 19 March 2015:


The US Food and Drug Administration (FDA) has approved Chord Therapeutics' application for orphan drug designation of cladribine to treat neuromyelitis optica and neuromyelitis optica spectrum disorder.